People

Amir Zamani is publicly listed by Bain Capital Life Sciences as Partner. Previously a McKinsey healthcare partner and a physician in plastic surgery training.

Amarilice Young is publicly listed by Bain Capital Life Sciences as Associate General Counsel. Previously a partner in Goodwin Procter’s life sciences practice.

Renjie Wang is publicly listed by Bain Capital Life Sciences as Managing Director. Healthcare transaction experience at Hony Capital before joining Bain.

John Trzupek, PhD is publicly listed by Bain Capital Life Sciences as Managing Director. Previously held executive roles at Abata Therapeutics and KSQ Therapeutics and scientific roles at Pfizer.

Ricky Lijing Sun is publicly listed by Bain Capital Life Sciences as Partner. Previously worked in corporate strategy at Biogen, healthcare investing and pharmaceutical research.

Daniyal Sachee is publicly listed by Bain Capital Life Sciences as Associate. Healthcare financing experience at Goldman Sachs and research involving rare epilepsy disorders.

Linus Rehn, MD is publicly listed by Bain Capital Life Sciences as Associate. Trained as a physician; earlier healthcare consulting at McKinsey and immuno-oncology research.

Lei Meng is publicly listed by Bain Capital Life Sciences as Managing Director. Therapeutics investing experience at Avidity Partners and pharmaceutical strategy roles.

Molly Lawrence is publicly listed by Bain Capital Life Sciences as Vice President, Human Resources, Life Sciences. Directs recruiting and employee development for life sciences, following talent roles at Audax.

Greg Koskinas is publicly listed by Bain Capital Life Sciences as Chief Financial Officer, Life Sciences. Leads life sciences finance; earlier operational and compliance responsibilities at ThornTree.

Chiaka Ibe is publicly listed by Bain Capital Life Sciences as Associate. Earlier healthcare consulting at Bain & Company and analysis at Gates Ventures.

Andrew Hack, MD, PhD is publicly listed by Bain Capital Life Sciences as Partner. Former CFO of Editas Medicine, with healthcare public-market investment experience.

Evan Greif is publicly listed by Bain Capital Life Sciences as Principal. Earlier healthcare investing at Orbis Investments and consulting at Bain & Company.

Alyson Goff is publicly listed by Bain Capital Life Sciences as Associate. Works in the life sciences Portfolio Group; earlier consulting experience at Guidehouse.

Drew Field is publicly listed by Bain Capital Life Sciences as Principal. Healthcare strategy consulting at Bain & Company and commercial roles in biotechnology.

Leonard Feiner, MD, PhD is publicly listed by Bain Capital Life Sciences as Principal. Former retinal surgeon and investigator in clinical trials for retinal diseases.

Nicholas Downing is publicly listed by Bain Capital Life Sciences as Partner. Trained as a physician and previously worked in strategic consulting at McKinsey.

Melissa Danforth is publicly listed by Bain Capital Life Sciences as General Counsel, Life Sciences. Earlier private equity legal work at Ropes & Gray and public service with the U.S. government.

Jennie Daisak is publicly listed by Bain Capital Life Sciences as Vice President. Healthcare investment banking experience with J.P. Morgan.

Will Cozean is publicly listed by Bain Capital Life Sciences as Managing Director. Earlier healthcare investing with Bain’s private equity team and operational consulting at McKinsey.

Michael Cooney, PhD is publicly listed by Bain Capital Life Sciences as Vice President. Genetics research at Harvard and vaccine development at Genocea Biosciences.

Isaac Cheng is publicly listed by Bain Capital Life Sciences as Vice President. Pharmaceutical strategy and business development at Johnson & Johnson and AbbVie.

Shuvam Chaudhuri, PhD is publicly listed by Bain Capital Life Sciences as Vice President. Doctoral immunology research at Northwestern and antiviral discovery research at Janssen.

Jonah Cashdan is publicly listed by Bain Capital Life Sciences as Principal. Healthcare investment banking at J.P. Morgan and neuroscience laboratory research.

Matthew Calistri is publicly listed by Bain Capital Life Sciences as Managing Director. Portfolio operations experience at Cerevel Therapeutics, Sage and Biogen.

Melaku Arega, MD is publicly listed by Bain Capital Life Sciences as Vice President. Clinical training at Harvard Medical School and research on disparities in cancer care.

Sharad Goyal is publicly listed by Bain Capital Life Sciences as Head of IT, Private Markets. Manages shared private markets technology functions, following technology consulting at Sapient.

Kristen Deftos is publicly listed by Bain Capital Life Sciences as Head of Human Resources, Double Impact, Life Sciences, Real Estate & Tech Opportunities. Leads talent acquisition and employee development across several Bain investment businesses.

Jay Corrigan is publicly listed by Bain Capital Life Sciences as Group Chief Financial Officer, Private Markets. Oversees shared private markets finance teams; previous experience at Ernst & Young.

Oriol Vinyals is a Frontier AI Partner at 224 Ventures, participating in sourcing, evaluation and voting on investments. The firm’s launch identifies him as a Discovery Loop co-founder and former Gemini co-lead at Google DeepMind.

Biotechnology scientist with experience in cell biology, screening and therapeutic discovery at Arbor, Obsidian, Sana and Novartis.

Operations executive with experience in medical devices, contract research and healthcare design; founded Caregiver Support Technologies.

Life-sciences finance executive with prior CFO experience at ImmunoGen, Aveo Oncology and Genzyme Biosurgery. Published in his biography as David B. Johnston.

AI and genomic-medicine researcher who founded Deep Genomics in 2015 and co-founded the Vector Institute; his research spans deep learning and genetic medicine.

Autism Impact Fund co-founder who founded the recruiting firm CPI in 1996. Previously worked in real estate at Jones Lang LaSalle and Morgan Stanley; graduated from Denison University. Distinct from the life sciences executive and Deep Genomics CEO of the same name.

Creative Director (UK) at Fifty Years. Director and producer whose films have screened at Cannes and Sundance London.

Designer of the Fifty Years brand. MFA, former design teacher in Kraków. Clients include Google, Stripe, GitHub, and the World Economic Forum.

Engineer at Fifty Years building AI tooling to find and support founders. Previously led data science at Dyson; earlier Sky, BAE Systems, and Fidessa.

Co-founder of Elicit.

Co-founder of Adaption Labs. Previously at Cohere.

Co-founder and CEO of Astranis.

CEO and co-founder of Vercept, a computer-use AI company acquired by Anthropic in 2026.

Founder and CEO of Nobell Foods (Alpine Bio), producing animal-free casein from soybeans. Previously a project manager at Shell.

Co-founder of LatchBio, a cloud platform for computational biology.

Co-founder of Wafer, an AI inference-optimization company. Previously at Google Bard / Two Sigma.

Co-founder of OnePot AI, an AI platform for chemical synthesis and drug discovery.

Co-founder of Elicit.

Co-founder and CEO of Aalo Atomics, building factory-made small nuclear reactors.

Co-founder of Adaption Labs. Previously at Cohere.

Ryan McLinko co-founded Astranis and serves as its chief technology officer.

UK Lead at Fifty Years. Co-founded Enapter (green hydrogen electrolyzers), which grew to about 250 people and listed publicly. Forbes 30 Under 30 Energy; Earthshot Prize winner.

Chief of Staff to Seth Bannon at Fifty Years. Linguistics background; based in Krakow, Poland.

UK Lead at Fifty Years. Biomedical researcher who co-founded Vellos with Sir Tony Kouzarides; Vellos partnered with Fifty Years to run 5050 UK.

Head of 5050 at Fifty Years. Runs recruiting, workshops, and founder retreats for the scientist-founder program. Previously led community work in Peru including Sigueme and Enseñame.

Head of Finance at Fifty Years (joined 2025). Previously EVP Finance at Wonderschool, Head of Strategic Finance at Miro, and an investor at EQT after BCG. Swiss Army officer and Harvard MBA.

Head of Engineering at Fifty Years. Previously Technical Lead, Core Developer Platform at Google; founder and VP Engineering at Raydiant.

Head of Product and Platform at Fifty Years. Previously PM at Facebook Groups/Messenger, Riot Games, and Microsoft Games. Builds internal tools and community for 50Y founders.

Chairman of the Board at Synchron. Managing Member, Neuro Technology Investors.

Chief of Staff and board member at Synchron. Former CEO of Dexcom.

Chief Clinical Officer of Paradromics.

Chief Commercial Officer of Synchron.

Chief Technology Officer of Ceribell. Joined 2016.

CTO of Zeto. Software engineer; previously eQ Online, Nordnet Bank, Crosskey.

Co-founder of Ceribell. Director of Stanford CCRMA.

Co-founder of Neuralink; President and COO. Doctoral work at UC Berkeley on Neural Dust.

CEO of Neuralink. Head of Elon Musk's family office.

Co-founder of Ceribell, board director and Chief Medical Advisor. Professor of neurology at Stanford.

Co-founder of Synchron. Founding Director; Head of Vascular Bionics Laboratory, University of Melbourne.

Medical Director and co-founder of Synchron.

Chief Medical Officer of Paradromics. Neurosurgeon; joined 2025.

CEO of Epitel. Former Dexcom EVP; appointed CEO February 2025.

Chief Scientific Officer of Paradromics. BCI veteran; joined 2023.

Chief Technology Officer of Paradromics.

Chief Operating Officer of Paradromics. Medical-device veteran; joined 2019.

MRI physicist at Karavela.

Data team lead at Karavela.

Models team lead at Karavela.

Co-founder and CSO of Karavela. Neuroimaging researcher.

Co-founder and CPO of Karavela.

Co-founder and majority owner of Neuralink.

Founder and CTO of Epitel. Neural engineer; University of Utah neurosurgery research background. Previously CEO until 2025.

Founder and CEO of Zeto. Electrical engineer (AMD) and MBA (UT Austin); built dry-electrode clinical EEG headsets after a family experience with epilepsy.

Founding CEO of Synchron. Interventional neurologist; developed the Stentrode endovascular BCI at the University of Melbourne.

Founder and CEO of Paradromics, a high-data-rate implantable BCI company in Austin.

Co-founder, President and CEO of Ceribell. PhD in biophysics from Cornell; previously McKinsey, Novartis and Genentech.

Co-founder and CEO of Karavela, an MRI-first brain foundation-model company in Paris.

Machine learning at Lys. Fulbright scholar; site lists CMU PhD in Robotics. Fulbright Bulgaria profile describes a 2022-23 visiting researcher stay at CMU Robotics Institute while completing a PhD at Technical University of Sofia.

Dr Navid Mohammadi Foumani is Foundation Model Architect & Lead at Dcode.AI and works at Emotiv / Emotiv Research in Melbourne. He is lead author of EEG2Rep (KDD 2024 Audience Appreciation Award) and EEG-X (arXiv:2511.08861). GitHub and Google Scholar list affiliations as Monash University and Emotiv.

Patrick Chu is VP of Software Engineering at Dcode.AI and VP of Engineering at Emotiv. The Dcode.AI team page says he has over 20 years in neurotechnology and leads development of Dcode's core platform. LinkedIn places him in Hong Kong.

Programmer and entrepreneur known as geohot; founder of comma.ai and tiny corp.